X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Natco Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
NATCO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs877360-   
Low Rs424259-   
Sales per share (Unadj.) Rs223.4107.0-  
Earnings per share (Unadj.) Rs31.1-27.0-  
Cash flow per share (Unadj.) Rs40.3-22.3-  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.584.0-  
Shares outstanding (eoy) m33.07168.78-   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.9 100.6%   
Avg P/E ratio x20.9-11.5 -182.3%  
P/CF ratio (eoy) x16.1-13.9 -116.5%  
Price / Book Value ratio x3.03.7 80.4%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50452,238 41.2%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m1,1283,279 34.4%   
Avg. sales/employee Rs ThNM4,205.5-  
Avg. wages/employee Rs ThNM763.7-  
Avg. net profit/employee Rs ThNM-1,059.7-  
INCOME DATA
Net Sales Rs m7,38918,054 40.9%  
Other income Rs m167126 132.2%   
Total revenues Rs m7,55618,181 41.6%   
Gross profit Rs m1,793-3,129 -57.3%  
Depreciation Rs m304779 39.1%   
Interest Rs m366489 74.9%   
Profit before tax Rs m1,290-4,271 -30.2%   
Minority Interest Rs m46-12 -388.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309267 115.7%   
Profit after tax Rs m1,027-4,549 -22.6%  
Gross profit margin %24.3-17.3 -140.1%  
Effective tax rate %23.9-6.2 -383.0%   
Net profit margin %13.9-25.2 -55.2%  
BALANCE SHEET DATA
Current assets Rs m3,68113,223 27.8%   
Current liabilities Rs m3,1237,440 42.0%   
Net working cap to sales %7.632.0 23.6%  
Current ratio x1.21.8 66.3%  
Inventory Days Days89111 80.7%  
Debtors Days Days59124 47.3%  
Net fixed assets Rs m7,6857,708 99.7%   
Share capital Rs m33184 394.5%   
"Free" reserves Rs m6,6700-   
Net worth Rs m7,25914,171 51.2%   
Long term debt Rs m9554,980 19.2%   
Total assets Rs m11,95726,770 44.7%  
Interest coverage x4.5-7.7 -58.5%   
Debt to equity ratio x0.10.4 37.4%  
Sales to assets ratio x0.60.7 91.6%   
Return on assets %11.7-15.2 -76.8%  
Return on equity %14.2-32.1 -44.1%  
Return on capital %20.7-19.8 -104.6%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Net fx Rs m2,7430-   
CASH FLOW
From Operations Rs m1,4401,541 93.5%  
From Investments Rs m-1,089-473 230.2%  
From Financial Activity Rs m-3534,520 -7.8%  
Net Cashflow Rs m-15,587 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.96 Rs / ZAR

Compare NATCO PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: UNICHEM LAB  STRIDES SHASUN LTD  ABBOTT INDIA  SUN PHARMA  AJANTA PHARMA  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views On News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 19, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS